GS
ALLO icon

Gilead Sciences’s Allogene Therapeutics ALLO Stock Holding History

Gilead Sciences’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,156,689
Closed -$1.31M – 10
2025
Q2 		$1.31M Hold
1,156,689
– – 0.1% 11
2025
Q1 		$1.69M Hold
1,156,689
– – 0.14% 11
2024
Q4 		$2.46M Buy
+1,156,689
New +$2.85M 0.16% 13

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Gilead Sciences's ALLO Position: Q3 2025 in Review

Gilead Sciences sold out of Allogene Therapeutics (ALLO) in Q3 2025, closing a stake of 1,156,689 shares — an estimated $1.31M sold.

Gilead Sciences first reported a position in ALLO in Q4 2024 and held it in 3 quarters. The position peaked at $2.46M in Q4 2024. 170 funds tracked by Wall St. Rank hold ALLO as of Q3 2025.

  • Gilead Sciences reported no remaining Allogene Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Gilead Sciences sold 1,156,689 Allogene Therapeutics shares in Q3 2025, an estimated $1.31M.
  • Gilead Sciences first reported a position in Allogene Therapeutics in Q4 2024 and held it in 3 quarters.
  • Gilead Sciences's Allogene Therapeutics position peaked at $2.46M in Q4 2024.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2025.

Based on Gilead Sciences's 13F filing for Q3 2025, filed 13 Nov 2025.